Secretion of Recombinant Interleukin-22 by Engineered Lactobacillus reuteri Reduces Fatty Liver Disease in a Mouse Model of Diet-Induced Obesity

Authors:

Abstract
In humans, nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease due to the increased prevalence of obesity. While treatment of NAFLD is often geared toward lifestyle changes, such as diet and exercise, the use of dietary supplements such as probiotics is underinvestigated. Here, we report that probioticLactobacillus reuterireduces fatty liver in a mouse model of diet-induced obesity. This phenotype was further enhanced upon delivery of recombinant interleukin-22 by engineeredLactobacillus reuteri. These observations pave the road to a better understanding of probiotic mechanisms driving the reduction of diet-induced steatosis and to development of next-generation probiotics for use in the clinic. Ultimately, these studies may lead to rational selection of (engineered) probiotics to ameliorate fatty liver disease.
Funding Information
  • Food Research Institute (233PRJ75PW)
  • UW-Madison Graduate School (135AAA2218)
  • UW-Madison ICTR funded by Natl. Center for Advancing Translational Science (UL1TR000427)
  • U.S. Department of Agriculture (2018-6717-27523)

This publication has 25 references indexed in Scilit: